PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics (NASDAQ: PTCT) has announced its participation in three major healthcare investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 8:35 a.m. ET, the Wells Fargo Healthcare Conference on September 4 at 11:00 a.m. ET, and the Morgan Stanley Global Healthcare Conference on September 8 at 9:15 a.m. ET.
All presentations will be available via webcast on PTC's investor relations website and will remain accessible for 30 days after each event.
Details
News Market Reaction – PTCT
On Aug 21, the day this news came out, PTCT closed 0.14% above the previous close.
Data tracked by StockTitan Argus for the Aug 21 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Cantor Global Healthcare Conference 2025
Wednesday, Sept. 3 at 8:35 a.m. ET
Wells Fargo 2025 Healthcare Conference
Thursday, Sept. 4 at 11:00 a.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Monday, Sept. 8 at 9:15 a.m. ET
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes before the start of the webcast to ensure a timely connection.
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on Facebook, X, and LinkedIn.
For More Information:
Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-302535211.html
SOURCE PTC Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.